Methods for cryopreservation
11612162 · 2023-03-28
Assignee
Inventors
Cpc classification
A01N1/0221
HUMAN NECESSITIES
A01N1/0294
HUMAN NECESSITIES
International classification
Abstract
The present invention relates to methods of cryopreservation and compositions for use in such methods where the methods utilise non-Newtonian fluid properties of the cryopreservation medium to modulate the viscosity of that medium to deliver an improved cryopreservation process.
Claims
1. A method for cryopreservation of a biological sample using a non-Newtonian fluid as a cryopreservation medium, wherein the method comprises applying a shear stress to control viscosity of the cryopreservation medium during a cryopreservation process, the process comprises the steps of: a) contacting the biological sample with the non-Newtonian fluid to produce a contacted biological sample; b) a first phase comprising applying the shear stress at a first shear rate to the contacted biological sample to produce a shear thinning stress to allow the cryopreservation medium to perfuse into the contacted biological sample to produce a perfused biological sample; and c) a second phase comprising cooling the perfused biological sample and applying the shear stress at a second shear rate to the perfused biological sample to produce a shear thickening stress to prevent formation of ice crystals during cooling of the perfused biological sample; wherein the method produces a cryopreserved biological sample; wherein the non-Newtonian fluid consists essentially of an aqueous suspension or an aqueous solution containing 2 wt % to 60 wt % of a non-Newtonian additive that is a particulate material with a mean particle size of 10 μm or less; and from 10 wt % to 40 wt % of a cryoprotective agent.
2. The method for cryopreservation of a biological sample according to claim 1, wherein applying the shear stress comprises applying a stress by mechanical, sonic, magnetic or electromagnetic field means thereto.
3. The method according to claim 1, wherein the shear stress is applied at a first amplitude during the first phase and the shear stress is applied at a different amplitude during the second phase.
4. The method according to claim 1, wherein the cryopreservation process comprises maintaining the shear thickening stress while cooling the sample to a temperature below the glass transition temperature of the biological sample.
5. The method according claim to claim 1, wherein the cooling occurs at a rate of 50° C. per minute or less.
6. The method according to claim 1, wherein the biological sample is maintained at a temperature below its glass transition temperature during the cooling of the biological sample.
7. The method according to claim 1, wherein the particulate material used as the non-Newtonian additive is selected from silica (SiO.sub.2), glass, titanium dioxide, calcium carbonate, alumina, quartz, iron oxide, a synthetic polymer, a starch or a biologically derived starch, or a mixture of two or more of these materials.
8. The method according to claim 1, wherein the cryoprotective agent is present at 10 wt % to 40 wt % in the cryopreservation medium, wherein the cryoprotective agent is selected from the group comprising dimethyl sulfoxide, formamide, acetamide, C.sub.1-C.sub.3 alcohols, 1,2-isopropyldiol, 1,2-propanediol, ethylene glycol, propylene glycol, glycerol, glucose, mono-saccharides, disaccharides, polysaccharides, ficoll, polyethylene glycol, polyvinylpyrollidine or a combination of two or more of these agents.
9. The method according to claim 7, wherein the non-Newtonian additive is a biologically derived polymer that is hydroxyethyl starch (HES) at a concentration of 45 wt % to 55 wt % in the cryopreservation medium.
10. A method for reconstituting a cryopreserved biological sample cryopreserved by the method according to claim 1, comprising the step of warming the cryopreserved biological sample to its glass transition point and applying a shear thickening stress at a temperature from below or at the glass transition temperature until the temperature of the cryopreserved biological sample rises above its freezing point.
11. The method of claim 1, wherein the first shear rate is between 10.sup.−4 s.sup.−1 to 0.5 s.sup.−1.
12. The method of claim 1, wherein the second shear rate is between 1 s.sup.−1 to 6 s.sup.−1.
13. A cryopreservation medium with non-Newtonian fluid properties, consisting essentially of an aqueous solution or an aqueous suspension containing between 50 wt % and 60 wt % by weight of a particulate material with a mean particle size of 10 μm or less, and between 10 wt % to 40 wt % of a cryoprotective agent.
14. The cryopreservation medium according to claim 13 wherein the cryoprotective agent is selected from the group consisting of dimethyl sulfoxide, formamide, acetamide, C.sub.1-C.sub.3 alcohols, 1,2-isopropyldiol, 1,2-propanediol, ethylene glycol, propylene glycol, glycerol, glucose, mono-saccharides, disaccharides, polysaccharides, ficoll, polyethylene glycol, polyvinylpyrollidine or a combination of two or more of these agents.
15. The cryopreservation medium according to claim 13 consisting of 50 wt % to 55 wt % hydroxyethyl starch (HES) as the particulate material, 5 wt % to 20 wt % of cryoprotective agent and water.
16. The cryopreservation medium according to claim 13, wherein the cryoprotective agent is selected from dimethylsulphoxide (DMSO) or a combination of DMSO and one or more of sucrose, glucose, glycerol, raffinose, fructose or lactose.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1) In order that the invention can be better understood reference is made to the following figure.
(2)
(3)
(4)
(5)
(6)
(7)
DETAILED DESCRIPTION
(8) In the methods of the invention the non-Newtonian fluid properties of the cryopreservation medium are exploited to modulate, i.e. increase (via shear thickening) or decrease (via shear thinning), the viscosity of the cryopreservation medium as appropriate for the phase of the cryopreservation process. Decreasing the viscosity of the cryopreservation medium can be advantageous as a cryoprotective agent (CPA) colloid solution may initially take many minutes to perfuse and/or diffuse into organic tissue and inducing some shear stress can lower this viscosity (i.e. the viscosity of the cryoprotective agent colloid solution or cryopreservation medium) so reducing perfusion time. As CPA toxicity is time-dependant, total toxicity during the perfusion state is reduced as a function of the reduced perfusion time.
(9) Increasing the viscosity of the cryopreservation medium by applying a shear stress as described herein can advantageously be used to prevent the formation of ice crystals in the sample while cooling to a temperature below the freezing point of water, thus substantially or completely eliminating the growth of ice crystals. This viscosity modulating effect is equally important during the thawing cycle as heating with an increased viscosity prevent or at least substantially reduces the chances of ice crystallisation at this stage of the cryopreservation process.
(10) Advantageously, some non-Newtonian fluids, for example some cryopreservation media of the invention can shear thin on application of a shear stress of a first amplitude or type and shear thicken on application of a shear stress of a first amplitude or type. As a result, the invention encompasses cryopreservation methods and cryopreservation media for use in such methods wherein the dual advantages of shear thinning and shear thickening in the cryopreservation process can be exploited in a single cryopreservation cycle.
(11) Another advantageous feature of increasing the viscosity of the cryopreservation medium by exploiting non-Newtonian fluid properties is that a rate of cooling can be applied that is much lower than those used in the vitrification methods of the art and thus renders practical cryopreservation of tissue samples and constructs that cannot be cryopreserved with the methods that form the state of the art.
(12) In addition, exploiting the non-Newtonian fluid properties of the cryopreservation medium may allow reduced amounts of cryoprotectant or cryoprotective additives (CPAs) and/or reduce the time required to perfuse and/or diffuse the CPAs into the sample and this advantageously reduces any toxic effects that a CPA may exert on a biological sample during the cryopreservation process. Decreasing the viscosity of the cryopreservation medium can also potentially improve fluid transport across the cell membrane by shifting the equilibrium ion or solute concentrations in the intracellular and extracellular domains and/or by accelerating ion/solute transport across the cell membrane thus accelerating the rate at which the equilibrium is obtained.
(13) Modification of the viscosity of the cryopreservation medium can be effected by applying an external stress to induce non-Newtonian properties. Induction of non-Newtonian properties can be achieved by shear thickening or shear thinning, by sound thickening or sound thinning, or by electromagnetic field thickening or thinning, for example magnetic thinning or thickening. Some preferred non-Newtonian fluids undergo a reduction in in viscosity when exposed to low frequency stress and undergo an increase in viscosity in response to a high frequency stress. Reference to shear thinning and shear thickening above and herein can refer to stress applied mechanically, sonically, magnetically or by electromagnetic radiation.
(14) Shear forces can be exerted for example by shaking (vibration), stirring (agitating), pressure waves or other mechanical means. For example, shear forces can be applied to a biological sample in a cryopreservation medium in turn in a cylindrical container by immersing a rod into the cryopreservation and then rotating the rod. Another example of a configuration in which a shear force could be applied to a sample would involve placing a biological sample in a cryopreservation medium between two parallel plates with either one or both of these plated moving parallel relative to the other. Shear thickening is the non-Newtonian behaviour wherein the viscosity of a fluid increases on the application of stress to a fluid. Shear thinning is the non-Newtonian behaviour of fluids whose viscosity decreases under shear stress. The fluid that undergoes shear thinning or shear thickening can be a solution or a suspension, for example a colloidal suspension. For example, the shear thickening fluid cryopreservation medium may be a suspension containing fine particles such as silica, a colloidal solution/suspension or a solution per se. This mechanism (i.e. the methods of the invention of cryopreservation that exploit the non-Newtonian fluid properties of a cryopreservation medium to deliver substantially ice free cryopreservation methods) is not isolated to only systems where CPAs are spiked with hard shell colloids such as silicone, HES, glass etc. Spiking with materials that enable electromagnetic field induced viscosity changes, sound and/or light induced viscosity changes, are also possible. This list is not exhaustive.
(15) Thus the methods of the invention allow for improved perfusion/diffusion and consequently reduced CPA toxicity by utilisation of a shear stress to reduce viscosity, subsequent utilisation of shear stress of a different amplitude or type can then be used to increase the viscosity of the cryopreservation medium and allow ice free cryopreservation at cooling rates much lower than those used for the ice free cryopreservation techniques of the art.
(16) An exemplary cryopreservation method according to the present invention comprises placing the sample to be preserved in a cryopreservation medium as described herein with non-Newtonian fluid properties prior to cooling to low temperature and then:
(17) i) applying a shear thinning stress for a first period of time sufficient to allow the cryopreservation medium to perfuse into the sample;
(18) ii) applying a shear thickening stress to increase the viscosity of the cryopreservation medium;
(19) iii) cooling the sample to a temperature below the glass transition temperature;
(20) iv) removing the shear thickening stress; and
(21) v) storing the resultant vitrified sample at low temperature.
(22) In methods described herein where a shear thickening stress is applied during cooling, the shear thickening stress is generally removed at a temperature around the glass transition temperature of the cryopreservation medium. For example, it is possible to remove the shear stress at a temperature the slightly above the glass transition temperature of the cryopreservation medium as the effect against ice nucleation will not dissipate immediately on removal of the stress. Nonetheless in these methods it is generally preferable to maintain the shear thickening stress until the sample has been cooled to the glass transition temperature or below.
(23) An alternative cryopreservation method according to the invention comprises placing the sample to be preserved in a cryopreservation medium as described herein with non-Newtonian fluid properties prior to cooling to low temperature and then:
(24) i) applying a shear thickening stress to increase the viscosity of the cryopreservation medium;
(25) ii) cooling the sample to a temperature below the glass transition temperature;
(26) iii) removing the shear thickening stress; and
(27) iv) storing the resultant vitrified sample at low temperature.
(28) An alternative cryopreservation method according to the invention comprises placing the sample to be preserved in a cryopreservation medium as described herein with non-Newtonian fluid properties prior to cooling to low temperature and then:
(29) i) applying a shear thinning stress for a first period of time sufficient to allow the cryopreservation medium to perfuse into the sample;
(30) ii) cooling the sample to a temperature below the glass transition temperature; and
(31) iii) storing the resultant vitrified sample at low temperature.
(32) The methods according to the invention may further comprise a warming step, i.e. the step of taking the low temperature cryopreserved sample and applying a shear thickening stress at a temperature from below, at, or above the glass transition temperature until the ice nucleation can no longer occur, for example at or near its equilibrium freezing point. Although it is generally preferred to initiate the shear thickening stress at, or below, the glass transition temperature of the cryopreservation medium, i.e. when the sample is still in a fully vitrified state, it is possible to allow the temperature to rise above the glass transition by a number of degree before applying the shear thickening stress. It is important to ensure that the shear thickening stress is applied in the temperature range where ice nucleation in the warming step is most probable, for example in the range of temperature from −80° C. to 0° C. or from −80° C. to the equilibrium freezing point). The warming rate is preferably less than 10° C. per minute, for example 1° C. per minute.
(33) An alternative cryopreservation method according to the invention comprises placing the sample to be preserved in a cryopreservation medium as described herein with non-Newtonian fluid properties prior to cooling to low temperature and then:
(34) i) cooling the sample to a temperature below the glass transition temperature;
(35) ii) storing the resultant vitrified sample at low temperature;
(36) iii) warming the sample to above its equilibrium freezing point;
(37) characterised in that a shear thickening stress that is initiated at a temperature below, at, or just above the glass transition temperature of the cryopreservation medium is applied to the sample during warming.
(38) The methods according to the invention may be performed at a cooling rate of less than or equal to 100° C. per minute for example 50° C. per minute and preferably less than 10° C. per minute, for example 1° C. per minute.
(39) The shear thinning or shear thickening stresses in the methods of the invention may be applied by mechanical, sonic, magnetic or electromagnetic radiation means.
(40) Upon sufficient perfusion for a given biological system, the viscosity of the colloidal suspension can be increased extremely rapidly until is exhibits solid-like properties. This has two major advantages which overcome current limitations in cryobiology: 1. The apparent toxicity of the solution will be greatly reduced—this is because molecular diffusion will be greatly reduced due to the high viscosity of the solution. As toxicity is related to metabolism of toxins, toxicity will be reduced through reduced diffusion rates around the cell membrane. 2. Ice formation will be inhibited through increased viscosity of the CPA colloid. The system will contain relatively little water compared with traditional ice-forming methods of cryopreservation. This will reduce the temperature at which ice forms and likelihood of individual nucleation events. The increased viscosity caused by the shear stress will inhibit ice formation, preventing ice damage.
(41) The system's temperature will be lowered until below the Tg (glass transition temperature). At this point, shear-stress can be discontinued with the system in a stable vitrified (amorphous solid) state. To thaw the system, sufficient shear-stress will be applied and the system warmed. This overcomes the problems faced with current state-of-the-art thawing devices:
(42) 1. Ice formation will be suppressed through the mechanism described above. This stops ice formation on warming without the need for rapid warming rates.
(43) 2. Toxicity will be reduced due to the mechanisms described above. Toxicity during CPA wash-out are also minimised through applying a suitable shear-force to reduce viscosity and thereby increase cell wash-out time.
(44) 3. Thermal stresses and thermal cracking are avoided through the relatively low cooling and warming rates required compared with current vitrification techniques.
(45) Materials that increase in viscosity under the application of a shear strain are sometimes referred to as dilatant materials. In some embodiments a dilatant cryopreservation medium, or in the plural, dilatant cryopreservation media, is/are preferred for use in the methods described herein.
(46) Non-Newtonian properties can be conferred to a cryopreservation medium by adding a defined amount of an additive that modulates the behaviour of a medium that otherwise essentially exhibits Newtonian fluid properties, i.e. whose viscosity does not vary under applied stress. The classes of additives that can be used to confer non-Newtonian behaviour are referred to herein as non-Newtonian additives (NNAs). NNAs are typically added to cryopreservation media in an amount of from 2 wt % to 60 wt per 100 g total mass of the resultant NNA containing cryopreservation medium. Any suitable NNA may be used in the method although for practical purposes the NNA is selected on the basis that it exerts no substantial toxic effect towards the sample to be preserved under the conditions of the technique. A mixture of NNAs in the specified range, from 2 wt % to 60% wt % may equally be used.
(47) In general terms, any suitable inorganic and organic particle may be used as a NNA. Typically, the mean particle size, i.e. the mean average longest linear dimension, of the NNA is 10 μm or less, for example 5 μm or less or preferably 1 μm or less. In some embodiments nanoparticulate NNAs are preferred. The term nanoparticle as used herein refers to particles with a mean particle size between 1 and 100 nm. Smaller particles can advantageously increase the non-Newtonian effect of the NNA and may accordingly be applied in a lower percentage in the cryopreservation medium than larger particles.
(48) In some embodiments the NNA can be an organic NNA, for example a biologically derived polymer such as a starch derivative or a synthetic polymer such as polystyrene or polyvinyl chloride. Preferred examples of NNAs that are starch derivatives include natural starches such as corn starches, potato starches, wheat starches and other plant derived starches and semi-synthetic starches such as hydroxyethyl starches (HES). In hydroxyethyl starches a plurality of hydroxyl ethyl substituents are introduced onto the hydroxyl groups of the glucose monomers from which the starch polymer backbone is constituted. Thus in some cases the hydroxyethyl starch (HES) may be a starch in which on average, one glucose hydroxyl group per every ten glucose units in the polymer may be substituted with a hydroxyethyl group while in heta starch the degree of substitution is typically from 7-8 hydroxyls per every 10 glucose units. The biocompatibility of HES starches is well known and the use of hydroxyethyl starch is accordingly preferred in some embodiments for cryopreservation of tissue samples and engineered tissue constructs. Cryopreservation media comprising from 45 wt % to 55 wt % of HES, for example from 48 wt % to 54 wt % have proven to have particularly favourable non-Newtonian properties.
(49) A wide range of fully synthetic polymers can be used as a NNA and in some advantageous embodiments may incorporate a functional core such as a ferromagnetic material. Thus particles of a polymer such as polystyrene, poly(methyl methacrylate), polyvinyl chloride or a similar biocompatible polymer can be used as a NNA. In other embodiments a polymer such as polyvinyl chloride, poly(methyl methacrylate), polystyrene or a similar biocompatible polymer can be used to coat a ferromagnetic material, for example iron oxide, for example to ensure or improve its biological compatibility to deliver a NNA that will modulate, e.g. increase or decrease, the viscosity of a cryopreservation medium in response to shear stress or variations in a magnetic field. For example, particles of a ferroelectric NNA can move in a linear or back and forth manner subject to an applied magnetic field and thus rapidly increase the viscosity of the medium, this in turn allows a steady ice-free cooling to be applied to bring the sample below its glass transition temperature (Tg) at which stage the sample undergoes vitrification.
(50) Inorganic NNAs are also suitable for use in the methods of the invention. Examples of inorganic NNAs include silica (SiO.sub.2), glass, titanium dioxide, alumina, quartz, a ferromagnetic material such as iron oxide, various clays and the like. Silica is a particularly preferred NNA as it can be readily obtained in defined particle size and purity and is water compatible. Iron oxide, for example in the form of nanoparticles, is also a preferred NNA as it is biocompatible and suitable for use in in vivo applications. Iron oxide allows for the application of shear thickening or thinning stress by application of a magnetic field. Iron oxide can be in the form of magnetite Fe.sub.3O.sub.4 or maghemite Fe.sub.2O.sub.3.
(51) As well as containing a NNA, the cryopreservation media that are used in the methods of the invention also comprise a cryoprotective agent (CPA). Use of CPAs in cryopreservation is well known. CPAs are used to mitigate some of the stresses experienced by a biological sample in the cryopreservation process. CPAs that are suitable for use in the methods of the invention are water soluble and generally form stable hydrogen bonds with water. The ability of CPAs to form stable hydrogen bonds with water molecules decreases the freezing point of the cryopreservation medium.
(52) The role of the CPA is manifold and depends on the context and concentration of its use. For example, a low molecular weight CPA may enter a cell during the cooling process and reduce the tendency for ice nucleation to occur during cooling. High molecular weight CPAs will not usually cross the cell membrane and accordingly exert their effects in the extracellular milieu. In lowering the freezing point of the extracellular fluid, a CPA can prevent excessive efflux of water from a cell thereby preventing a cell's shrinkage beyond its minimum critical volume. By reducing cellular retraction, CPAs can attenuate hyperconcentration of intracellular fluid and thereby inhibit the precipitation of protein. Ideally the CPA will be able to perfuse into a biological sample at a sufficient rate to exert its protective effect, the advantageously slow cooling rates of the methods of the present invention compared to the vitrification methods of the prior art in which cooling rates of 10,000° C. per minute are common allows for progressive perfusion during the cooling phase of the cryopreservation process. CPAs can also prevent generation of excessive salt concentrations during the freezing process that can be toxic to the cell. For example, in a solution the relative concentration of the solute will increase as the solvent in which it is dissolved solidifies (freezes).
(53) Any suitable CPA or combination of CPAs may be used in the methods of the invention. Examples of well known CPAs that may be used alone or in combination in the methods of the invention are dimethyl sulfoxide, formamide, acetamide, C.sub.1-C.sub.3 alcohols, 1,2-isopropyldiol, 1,2-propanediol, ethylene glycol, propylene glycol, glycerol, glucose, mono-saccharides, disaccharides (for example sucrose, trehalose, lactose), polysaccharides (for example raffinose, dextran), ficoll, polyethylene glycol, polyvinylpyrollidine. The selection of CPA will be dependent to a certain extent on the nature of the sample to be cryopreserved. Thus transmission of the CPA across a cell membrane will not be an important consideration when preserving protein samples whereas for preservation of cells, tissues and engineered tissue constructs this will be a greater factor. Likewise, it will be apparent to the skilled person that the ability of a CPA to perfuse/diffuse into a sample is more important for tissue samples relative to isolated cells.
(54) Typically, the concentration of the CPA or the sum of concentrations of CPAs in the cryopreservation medium in the methods of the invention is less than or equal to 50 wt % and usually less than or equal to 40 wt %, for example from 10 wt % to 40 wt %. At concentrations below 10 wt % of the CPA ice nucleation becomes a more significant factor.
(55) Examples of cryoprotective agents that can be used in methods of the invention include, but are not limited to, low molecular weight (Mr<400) CPAs that can cross cell membranes are alcohols such as methanol, ethanol, 1,2-isopropyldiol, 1,2-propanediol, glycerol, ethylene glycol, formamide, acetamide and dimethylsulfoxide and higher molecular weight and/or non-penetrating CPAs such as monosaccharides (for example glucose), disaccharides (for example sucrose, trehalose, lactose), polysaccharides (raffinose, dextran), ficoll, polyethyleneglycol polyvinylpyrrolidinone and foetal bovine serum. Particularly preferred CPAs are DMSO, glycerol, glucose, propylene glycol, and polyethylene glycol.
(56) The ice free vitrification methods of the state of the art that are typically in the range of hundreds of degrees Celsius and are often of the order of 10,000° C. per minute. As mentioned above the cooling rates used in the methods of the present invention are much slower than those in the ice free vitrification methods of the art and are less than or equal to 100° C. per minute for example 50° C. per minute and preferably less than 10° C. per minute, for example from 1° C. to 10° C. per minute or 1° C. per minute. The use of these relatively slow cooling rates advantageously enables cryopreservation of samples that are much larger than those that can be preserved with the ice free vitrification methods of the art. Ultimately the precise rate of cooling will be a function of the size and composition of the sample but the rates outlined above have proved to be the suitable working ranges for the cryopreservation techniques described herein.
(57) The ice free methods of the present invention have a wide scope of application and are particularly advantageous for samples that are too large to undergo ice free cryopreservation with the methods of the state of the art. For example, many tissues and tissue engineered organs have no, or extremely limited (typically no more than a few hours), shelf lives after removal from the host organism/patient/culture. The limited shelf life leads to excessive waste and results in the cost of using such samples being greatly increased. As a result, Just-in-Time manufacture is usually not feasible for tissue engineered constructs. The methods of the invention thus offer great advantages for the development of regenerative medicine based on tissue engineered constructs such as stem-cell based composite tissue constructs. Such constructs could be preserved with the methods of the invention and this would enable tissue engineered samples to be stored and used in an “off the shelf” manner and as a result radically improve the economics and availability of therapeutic interventions based on such samples.
(58) The invention also provides compositions for use as cryopreservation media in the methods of the invention.
(59) The cryopreservation medium compositions of the invention are aqueous solutions or suspensions comprising from 10 wt % to 40% wt % of a cryoprotective agent (CPA) and from 2 wt % to 60 wt % of a non-Newtonian additive (NNA) that is a biocompatible particulate material with a mean longest average linear dimension 10 μm or less. In some embodiments the cryopreservation medium is a starch free aqueous solution or suspension comprising from 10 wt % to 40 wt % of a cryoprotective agent (CPA) and from 2 wt % to 60 wt % of a non-Newtonian additive (NNA) that is a biocompatible particulate material with a mean longest average linear dimension 10 μm or less. As used herein the term starch free refers to compositions that do not contain starch or any semi-synthetic starch derivative such as hydroxyethyl starch.
(60) The non-Newtonian additive is an organic or inorganic particulate material with a mean longest average linear dimension 10 μm or less. In some embodiments the non-Newtonian additive has a mean longest average linear dimension 1 μm or less. In some embodiments the non-Newtonian additive is in nanoparticle form, for example iron oxide particles with a mean average longest linear dimension of from 1 to 100 nm.
(61) The particulate material used as a NNA is generally selected from the group comprising silica (SiO.sub.2), glass, titanium dioxide, alumina, quartz, iron oxide, a synthetic polymer or a biologically derived polymer mixture of two or more of these materials. In some embodiments the biologically derived polymer is a natural starch or a derivative thereof, for example hydroxyethyl starch. In some examples the particulate material is silica, for example silica balls. In some examples the particulate material is iron oxide, optionally iron oxide nanoparticles. In examples the particulate material is a ferromagnetic material encapsulated in a polymeric matrix.
(62) In some examples the cryoprotective agent is selected from group comprising dimethyl sulfoxide, formamide, acetamide, C.sub.1-C.sub.3 alcohols, 1,2-isopropyldiol, 1,2-propanediol, ethylene glycol, propylene glycol, glycerol, glucose, mono-saccharides, disaccharides (sucrose, trehalose, lactose), polysaccharides (raffinose, dextran), ficoll, polyethylene glycol, polyvinylpyrollidine or a combination of two or more of these agents. In some examples the cryoprotective agent is selected from dimethyl sulfoxide, glycerol, glucose, propylene glycol, and polyethylene glycol or a combination of two or more of these CPAs. In some preferred examples the cryoprotective agent comprises dimethyl sulfoxide.
(63) The invention therefore provides a smart material that reduces toxicity, reduces thermal stresses, and inhibits ice formation during cryopreservation of biologics (biological samples). Spiking chemicals (CPAs) used in cryopreservation such as glycerol, dimethylsulphoxide, sugars, alcohols, polyethylene glycol, ethylene glycol, with small (<10 μm) solid particles such as silica balls, nanoparticles, HES, and/or SiO.sub.2 can be used as a method to cryopreserve biological samples through non-Newtonian fluid properties being exploited by way of increasing and/or decreasing the viscosity of the solution used to achieve cryopreservation.
(64) The smart materials are those where any (spiking) chemical (CPA) used is recorded as having temperature dependant cell-membrane stabilization effects, reduces the likelihood of intracellular ice, suppresses the freezing point of a water-based solution, reduces the likelihood of ice formation, lowers the equilibrium melting point of a water based solution, reduces cold-shock or cold-temperate related injuries, or protects against any other cryopreservation related injury, or any combination of these.
(65) The solid particles used induce non-Newtonian behaviour through shear-thickening and/or thinning, sound thickening and/or thinning, electromagnetic field thickening and/or thinning, electromagnetic radiation thickening and/or thinning. Or any other non-Newtonian mechanism, or combination of these.
(66) The invention also relates to the use of a particulate material having a mean particle size of 10 μm or less to confer non-Newtonian fluid properties to a cryopreservation medium. Examples of the particulate materials that are suitable for this use are starch or a starch derivative such as hydroxyethyl starch, silica, silica (SiO.sub.2), glass, titanium dioxide, alumina, quartz, iron oxide or a synthetic polymer such as polyvinyl chloride or polystyrene.
(67) The non-Newtonian additive can be provided in a package, for example an aseptic package, optionally in combination with the requisite amount of CPA for reconstitution with a defined amount of water and/or the CPA. The cryopreservation media described herein and above can be supplied as a package, for example an aseptic package, ready for use in a cryopreservation method described herein and above. The packages, for example aseptic packages, could be stored ready for use to allow cryopreservation to be performed on fresh samples as soon as they become available and thus improving the cryopreservation success rate.
(68) As will be appreciated by the person skilled in the art the preferred embodiments for each element of the method or the compositions described above may be freely combined. Such combination provides embodiments that feature, for example, the preferred composition ranges and natures of the components of the cryopreservation media or the preferred steps of the method. Thus, a non-Newtonian additive, with the particle size, molecular identity and the composition ranges (% by weight) specified herein can be freely combined with the composition ranges and molecular identity of the cryoprotective agent as an aqueous solution to give the preferred compositions for use in the methods of the invention or for provision as a product for use, for example in the form of an aseptic package.
(69) Further embodiments of the present invention are set out in the following numbered clauses: 1. A smart material that reduces toxicity, reduces thermal stresses, and inhibits ice formation during cryopreservation of biologics. Spiking chemicals used in cryopreservation as glycerol, dimethylsulphoxide, sugars, alcohols, polyethylene glycol, ethylene glycol, with small (<10 μm) solid particles such as silica balls, nanoparticles, HES, and/or SiO.sub.2 can be used as a method to cryopreserve biological samples through non-Newtonian fluid properties being exploited by way of increasing and/or decreasing the viscosity of the solution used to achieve cryopreservation. 2. As 1, where any chemical used is recorded having temperature dependant cell-membrane stabilization effects, reduces the likelihood of intracellular ice, suppresses the freezing point of a water-based solution, reduces the likelihood of ice formation, lowers the equilibrium melting point of a water based solution, reduces cold-shock or cold-temperate related injuries, or protects against any other cryopreservation related injury, or any combination of these. 3. As 1, where the solid particles used induce non-Newtonian behaviour through shear-thickening and/or thinning, sound thickening and/or thinning, electromagnetic field thickening and/or thinning, electromagnetic radiation thickening and/or thinning. Or any other non-Newtonian mechanism, or combination of these. 4. As 1 and 3, where the particles used are either molecular, ions, not in the solid state, or not of homogeneous composition, or any combination of these. 5. As 1, 2, 3, and 4, where the non-Newtonian material consists of more than two components, whether that be a combination of those described in 2, a combination of those described in 3, a combination of those described in 4, or any combination of the above.
(70) So that the invention may be better understood a number of examples are provided herein of cryopreservation media according to the invention and their non-Newtonian fluid behaviour. Those skilled in the art will realise that these and similar cryopreservation media comprising an aqueous solution of a CPA in which a non-Newtonian additive is incorporated can be used in the methods of the invention as defined herein and in particular in the appended claims.
EXAMPLES
(71) A solution of 25% water, 25% DMSO, and 50% HES (all by weight) was prepared. This solution was stirred with a stirring rod until completely mixed. The mix was then added to a RheoLab QC Rheometer (Anton-Paar, Graz, Austria) with a concentric cylinder measuring device. The viscosity of the solution was measured at shear rates of between 0.01/s to 2/s. It was found that at increasing shear rates <0.5/s the mix exhibited increasing shear-thinning. At a critical point between 0.5 and 1/s the behaviour of the mix changed markedly to shear thickening. Similar behaviour was also seen in a solution containing 50% HES by weight in water.
(72) A number of additional experiments were performed to parameterise the effect of non-Newtonian additives on the fluid behaviour of cryopreservation media under shear stress.
(73) Shear Thinning and Shear Thickening Effects in Cryopreservation Media Comprising a Non-Newtonian Additive
(74) The non-Newtonian behaviour of cryopreservation media comprising various amounts of HES as the non-Newtonian additive in conjunction with various cryoprotectants and water was studied. The results from this study are presented in
(75) TABLE-US-00001 TABLE 1 Cryopreservation media compositions evaluated in FIG. 1 Non-Newtonian Composition Additive Cryoprotectant Water A 54 wt % HES 10 wt % DMSO 36 wt % B 50 wt % HES 10 wt % DMSO 40 wt % C 45 wt % HES 10 wt % DMSO 45 wt %
(76) In these experiments, a candidate non-Newtonian cryopreservation medium sample was placed in a chamber defined by two co-axial cylindrical walls projecting upwards from a floor. A hollow cylinder, coupled to a motor to drive its rotation, i.e. the rheometer, was then immersed in the sample located in the chamber. The hollow cylinder was then rotated at a measured rate, the shear rate y, the shear stress was measured by comparing the speed of rotation to the torque required to attain that speed of rotation. Shear rate was defined by the velocity of the hollow cylinder's movement divided by the gap between the hollow cylinder and the chamber edges. The torque required to achieve rotation of the hollow cylinder in the sample was recorded and could be used to determine the viscosity of the solution. Variation of the viscosity as a function of the variation in shear rate could accordingly be established.
(77) As can be seen in
(78) It was thus demonstrated that shear thinning and shear thickening behaviour in a single sample could be achieved solely by varying the shear rate (and thus the shear stress) to which the sample is subjected. Shear thickening behaviour was observed for compositions B and C. From this study it appears that 45 wt % to 54 wt % HES exhibits non-Newtonian behaviour, with scales of viscosity change more pronounced at 50 wt % and above.
(79) Variation in Shear Thickening Effect as a Function of Cryoprotectant
(80) An experiment was performed to determine whether the cryoprotectant has an effect on the shear thickening behaviour at room temperature, data from this study is presented in
(81) Impact of Temperature on Shear Thickening in Various Non-Newtonian Additive Containing Cryopreservation Media of Composition Containing HES, CPA and H.sub.2O
(82) Experiments were then performed to establish whether the non-Newtonian behaviour would vary as a function of temperature, since in the intended application it is essential that the non-Newtonian behaviour is manifest at low temperature.
(83) TABLE-US-00002 TABLE 2 Cryopreservation media compositions evaluated in FIG. 3 Non-Newtonian Additive Cryoprotectant Water FIG. 3A 50 wt % HES 10 wt % glucose 40 wt % FIG. 3B 50 wt % HES 10 wt % raffinose 40 wt % FIG. 3C 50 wt % HES 10 wt % sucrose 40 wt % FIG. 3D 50 wt % HES 10 wt % DMSO 40 wt % FIG. 3E 50 wt % HES 10 wt % lactose 40 wt % FIG. 3F 50 wt % HES 10 wt % fructose 40 wt % FIG. 3G 45 wt % HES 10 wt % sucrose 45 wt % FIG. 3H 50 wt % HES 10 wt % sucrose 35 wt % 5 wt % DMSO
(84) The results for non-Newtonian additive containing cryopreservation media according to the invention having a 50% HES/10% CPA/40% H.sub.2O composition (% by weight) are shown in
(85) The results displayed in
(86) Impact of Temperature on Shear Thickening
(87) In order to further inspect the temperature dependence of the shear thickening effect an experiment in which the shear thickening of a 50 wt % HES/15 wt % CPA/35 wt % H.sub.2O cryopreservation medium was evaluated as a function of temperature from −9° C. to 50° C. was performed. The results of this study are presented in
(88) Shear Thinning of Silica and Calcium Carbonate Containing Cryopreservation Medium Compositions
(89) As noted above, non-Newtonian additives can be useful for providing shear thinning properties to a viscous cryopreservation media. The non-Newtonian fluid properties of the aqueous SiO.sub.2 compositions of Table 3 were evaluated and significant shear thinning was observed (see
(90) TABLE-US-00003 TABLE 3 Compositions of FIG. 5 Composition Non-Newtonian Additive Water A 60 wt % SiO2 40 wt % B 50 wt % SiO2 50 wt % C 40 wt % SiO2 60 wt %
(91) TABLE-US-00004 TABLE 4 Compositions of FIG. 6 Composition Non-Newtonian Additive Cryoprotectant Water A 50 wt % CaCO3 10 wt % DMSO 40 wt % B 50 wt % CaCO3 10 wt % glycerol 40 wt %